(S)-3-<(phenylmethoxy)carbonyl>-4-oxazolidinecarboxylic acid methyl ester | 126111-22-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-3-<(phenylmethoxy)carbonyl>-4-oxazolidinecarboxylic acid methyl ester
• 英文别名: (S)-(-)-3-(benzyloxycarbonyl)-4-oxazolidinecarboxylic acid methyl ester；(S)-3-[(phenylmethoxy)carbonyl]-4-oxazolidinecarboxylic acid methyl ester；(s)-(-)-3-(Benzyloxycarbonyl)-4-oxazolidinecarboxylic methyl ester；3-O-benzyl 4-O-methyl (4S)-1,3-oxazolidine-3,4-dicarboxylate
• CAS: 126111-22-6
• 化学式: C₁₃H₁₅NO₅
• 分子量: 265.266
• InChiKey: KAUPOLAFYURMQR-NSHDSACASA-N

物化性质

• 沸点：
  384.7±42.0 °C(Predicted)
• 密度：
  1.283±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  65.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (S)-3-<(phenylmethoxy)carbonyl>-4-oxazolidinecarboxylic acid methyl ester 在 palladium dihydroxide 4-二甲氨基吡啶 、 氢气 、 三乙胺 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 反应 17.5h， 生成 *,R^*)>-3-<2-(2,2-dimethyl-1-oxopropoxy)-1-oxo-6-<<(phenylmethoxy)carbonyl>amino>hexyl>-4-oxazolidinecarboxylic acid methyl ester
  参考文献：
  名称：

  (Phosphinyloxy)acyl amino acid inhibitors of angiotensin converting enzyme. 2. Terminal amino acid analogs of (S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L-proline

  摘要：

  Analogues of (S)-1-[6-amino-2[[hydroxy(4-phenylbutyl)phosphinyl] oxy]-1-oxohexyl]-L-proline (1, SQ 29,852) in which the terminal proline residue has been replaced by a variety of substituted and heteroatom-substituted prolines, N-arylglycines, N-cycloalkylglycines, and bicyclic amino acids have been synthesized and evaluated as inhibitors of angiotensin converting enzyme in vitro and in vivo. In general, the addition of lipophilic substituents to the 4-position of proline of the parent phosphonate 1 resulted in substantial increases in in vitro activity. The largest improvements were observed in the case of cis-benzyl (36-fold) and dithioketal (24-fold) analogues 2r and 2x, respectively. These enhancements of in vitro activity were accompanied by modest increases (2-3.5-fold) in in vivo (iv) activity. Among the various terminal amino acid replacements examined in this study, the indoline-based analogue 2i was by far the most potent compound on iv administration in the normotensive rat.

  DOI：

  10.1021/jm00167a028
• 作为产物：
  描述：

  甲醇 、 (S)-(+)-3-(苄氧羰基)-恶唑烷-4-羧酸 在 氯化亚砜 、 碳酸氢钠 作用下， 以 甲醇 、 水 为溶剂， 以99%的产率得到(S)-3-<(phenylmethoxy)carbonyl>-4-oxazolidinecarboxylic acid methyl ester
  参考文献：
  名称：

  [EN] NOVEL BENZODIAZEPINE DERIVATIVES
  [FR] NOUVEAUX DÉRIVÉS DE BENZODIAZÉPINE

  摘要：

  该发明涉及具有抗增殖活性的新型苯二氮䓬啶衍生物，更具体地涉及具有式(I)和(II)的新型苯二氮䓬啶化合物，其中二氮䓬啶环(B)与杂环环(CD)融合，其中杂环环是双环的或式(III)的化合物，其中二氮䓬啶环(B)与杂环环(C)融合，其中杂环环是单环的。该发明提供了这些化合物的细胞毒性二聚体。该发明还提供了单体和二聚体的结合物。该发明进一步提供了使用该发明的化合物或结合物抑制异常细胞生长或治疗哺乳动物增殖性疾病的有效组合物和方法。该发明还涉及使用该发明的化合物或结合物进行体外、原位和体内诊断或治疗哺乳动物细胞或相关病理条件的方法。

  公开号：

  WO2010091150A1

文献信息

• NOVEL BENZODIAZEPINE DERIVATIVES
  申请人：Li Wei

  公开号：US20100203007A1

  公开（公告）日：2010-08-12

  The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

  本发明涉及具有抗增殖活性的新型苯二氮平衍生物，更具体地涉及公式（I）和（II）的新型苯二氮平，其中二氮平环（B）与杂环环（CD）融合，其中杂环环为双环或公式（III）的化合物，其中二氮平环（B）与杂环环（C）融合，其中杂环环为单环。本发明提供这些化合物的细胞毒性二聚体。本发明还提供单体和二聚体的结合物。本发明还提供使用该发明的化合物或结合物抑制异常细胞生长或治疗哺乳动物增殖性疾病的组合物和方法。本发明还涉及使用该化合物或结合物进行哺乳动物细胞的体外、原位和体内诊断或治疗，或相关病理条件的方法。
• Benzodiazepine derivatives
  申请人：Li Wei

  公开号：US08809320B2

  公开（公告）日：2014-08-19

  The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

  本发明涉及具有抗增殖活性的新型苯二氮平衍生物，更具体地涉及公式（I）和（II）的新型苯二氮平，其中二氮平环（B）与杂环环（CD）融合，其中杂环环为双环或公式（III）的化合物，其中二氮平环（B）与杂环环（C）融合，其中杂环环为单环。本发明提供了这些化合物的细胞毒性二聚体。本发明还提供了单体和二聚体的结合物。本发明还提供了使用本发明的化合物或结合物用于抑制异常细胞生长或治疗哺乳动物增殖性疾病的组合物和方法。本发明还涉及使用本发明的化合物或结合物进行哺乳动物细胞的体外、原位和体内诊断或治疗，或相关病理条件的方法。
• KARANEWSKY, DONALD S.;BADIA, MICHAEL C.;CUSHMAN, DAVID W.;DEFORREST, JACK+, J. MED. CHEM., 33,(1990) N, C. 1459-1469
  作者：KARANEWSKY, DONALD S.、BADIA, MICHAEL C.、CUSHMAN, DAVID W.、DEFORREST, JACK+

  DOI：——

  日期：——
• US8426402B2
  申请人：——

  公开号：US8426402B2

  公开（公告）日：2013-04-23
• US8802667B2
  申请人：——

  公开号：US8802667B2

  公开（公告）日：2014-08-12